Hims & Hers Health announced Wednesday it has acquired New Jersey-based at-home lab testing facility Trybe Labs.The deal will allow the telehealth company to offer at-home blood draws and more comprehensive pre-treatment testing to its users."Access to richer data allows us to deepen the insights that providers can use on our platform to guide their clinical decisions for each individual patient," said Dr. Patrick Carroll, Hims & Hers chief medical officer."At-home lab testing is one more exciting step towa ...

I recently joined The REIT Forum and if you are looking for more investment ideas like this one, get them exclusively at The REIT Forum with access to our subscriber only portfolios.With the stock exceeding my previous price target and up 212% since then, it has outperformed the S&P 500 by over 50x.Amrita runs a boutique family office fund in beautiful Vancouver, where she leads the investment strategy for the family fund. The fund's objective is to invest capital in sustainable, growth-driven companies tha ...

The stock isn't as expensive as you might think.Shares of Hims & Hers (HIMS -1.01%) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the company's high short interest in this video.*Stock prices used were end-of-day prices of Feb. 16, 2025. The video was published on Feb. 18, 2025. ...

The stock is up 140% this year already.In this video, I will talk about recent updates regarding Hims & Hers Health (HIMS -1.01%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Feb. 14, 2025. The video was published on Feb. 14, 2025. ...

Hims & Hers Health, Inc.’s (HIMS) investors have been experiencing some short-term gains from the stock of late. Shares of the San Francisco, CA-based health and wellness platform have surged 156.9% in the past three months, outperforming the industry’s 28.3% gain. In the same time frame, the stock outperformed the sector and S&P 500’s 0.3% rise and 3.6% growth, respectively.Two major developments of HIMS in recent months include the announcement of its promising third-quarter 2024 results and the launch of ...

The stock has sprinted past $50 per share, after trading at $3 less than two years ago.Shares of direct-to-consumer telehealth platform Hims & Hers Health (HIMS 2.18%) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a blistering 490% over the past year alone. Those who got in early may have already made life-changing money on this stock.Its momentum is no fluke. The company has continually touted robust growth, driven by a subscriber base that ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $60.30, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily loss of 0.01%. On the other hand, the Dow registered a loss of 0.37%, and the technology-centric Nasdaq increased by 0.41%.Shares of the company have appreciated by 111.81% over the course of the past month, outperforming the Medical sector's gain of 3.39% and the S&P 500's gain of 4.88%.Analysts and investors alike will be keepin ...

SYDNEY, AUSTRALIA - JANUARY 13: Ozempic is medicine for adults with type 2 diabetes . Wegovy is ... [+] prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia (Photo by Steve Christo - Corbis/Corbis via Getty Images)Corbis via Getty ImagesThe stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has surged an impressive 43% over the past week. A major driver of this growth was the company's widel ...

Company Overview - Hims & Hers Health, Inc. (HIMS) shares increased by 27.7% in the last trading session, closing at $59.18, with a notable trading volume compared to typical sessions [1] - The stock has experienced a significant 66.3% gain over the past four weeks, reaching a new all-time high following a successful Super Bowl advertisement [1] Earnings Expectations - The company is projected to report quarterly earnings of $0.12 per share, reflecting a year-over-year increase of 1100% [2] - Expected revenues for the upcoming report are $471.42 million, which is a 91.2% increase from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Hims & Hers Health has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [3] Industry Context - Hims & Hers Health operates within the Zacks Medical Info Systems industry, which includes other companies like Nyxoah SA (NYXH) [3] - Nyxoah's consensus EPS estimate for its upcoming report is -$0.48, representing a 17.1% decline from the previous year, and it also holds a Zacks Rank of 3 (Hold) [4]

Big pharma tried to stop Hims & Hers' Super Bowl ad.Hims & Hers (HIMS 1.51%) launched a Super Bowl ad this week, and everyone from pharmaceutical companies to pharmacists tried to block it. Travis Hoium explains why that's a great sign that the company's disruptive potential is real.*Stock prices used were end-of-day prices of Feb. 11, 2025. The video was published on Feb. 12, 2025. ...